1. Home
  2. BAH vs IMVT Comparison

BAH vs IMVT Comparison

Compare BAH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Booz Allen Hamilton Holding Corporation

BAH

Booz Allen Hamilton Holding Corporation

HOLD

Current Price

$71.15

Market Cap

9.6B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$38.51

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAH
IMVT
Founded
1914
2018
Country
United States
United States
Employees
31500
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
8.0B
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
BAH
IMVT
Price
$71.15
$38.51
Analyst Decision
Hold
Buy
Analyst Count
11
8
Target Price
$97.00
$33.00
AVG Volume (30 Days)
2.4M
951.3K
Earning Date
05-22-2026
05-28-2026
Dividend Yield
3.09%
N/A
EPS Growth
N/A
N/A
EPS
1.63
N/A
Revenue
$11,217,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.14
N/A
P/E Ratio
$42.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$59.50
$14.32
52 Week High
$114.48
$41.23

Technical Indicators

Market Signals
Indicator
BAH
IMVT
Relative Strength Index (RSI) 57.78 50.26
Support Level $68.84 $37.53
Resistance Level $82.96 $41.22
Average True Range (ATR) 2.83 1.49
MACD 0.88 -0.38
Stochastic Oscillator 63.47 36.57

Price Performance

Historical Comparison
BAH
IMVT

About BAH Booz Allen Hamilton Holding Corporation

Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: